DXCM vs STAA: fair value comparison
DexCom, Inc. and STAAR Surgical Company · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STAA currently sits closer to the top of our discount ranking. STAA carries the stronger quality grade.
| DXCM | STAA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $83.03 | $23.52 |
| 12-month range | $58.22–$90.14 | $18.04–$29.55 |
| Sector rank | #19 of 113 Healthcare | #15 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | B | — |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: DXCM fair value analysis · STAA fair value analysis